NICE guidance supports the use of GLP-1 receptor agonists for type 2 diabetes (NG28) when certain criteria are met, typically after other treatments have been tried
DB enhances insulin release through mechanisms involving KATP channels, bitter taste receptor signaling, and intraislet GLP-1 secretion
Anyiam, O., et al., How do glucagon-like Peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta-analysis
We dont rely on BMI aloneprescribing decisions are based on overall metabolic and health needs
34 GCGR is expressed in the liver, brain, kidney, GIT, pancreatic alpha and beta-cells, heart and adipose tissue
As with any prescription medicine, the dose prescribed is for you and you alone